Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives

Misfolded proteins, inflammation, and vascular alterations are common pathological hallmarks of neurodegenerative diseases. Alpha-synuclein is a small synaptic protein that was identified as a major component of Lewy bodies and Lewy neurites in the brain of patients affected by Parkinson's disease (PD), Lewy body dementia (LBD), and other synucleinopathies. It is mainly involved in the regulation of synaptic vesicle trafficking but can also control mitochondrial/endoplasmic reticulum (ER) homeostasis, lysosome/phagosome function, and cytoskeleton organization. Recent evidence supports that the pathological forms of α-synuclein can also reduce the release of vasoactive and inflammatory mediators from endothelial cells (ECs) and modulates the expression of tight junction (TJ) proteins important for maintaining the blood–brain barrier (BBB). This hints that α-synuclein deposition can affect BBB integrity. Border associated macrophages (BAMs) are brain resident macrophages found in association with the vasculature (PVMs), meninges (MAMs), and choroid plexus (CPMs). Recent findings indicate that these cells play distinct roles in stroke and neurodegenerative disorders. Although many studies have addressed how α-synuclein may modulate microglia, its effect on BAMs has been scarcely investigated. This review aims at summarizing the main findings supporting how α-synuclein can affect ECs and/or BAMs function as well as their interplay and effect on other cells in the brain perivascular environment in physiological and pathological conditions. Gaps of knowledge and new perspectives on how this protein can contribute to neurodegeneration by inducing BBB homeostatic changes in different neurological conditions are highlighted.

[1]  Jia-Yi Li,et al.  Human α-synuclein overexpression in a mouse model of Parkinson’s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation , 2021, Scientific Reports.

[2]  M. Cookson,et al.  Extracellular clusterin limits the uptake of α‐synuclein fibrils by murine and human astrocytes , 2020, Glia.

[3]  D. Krainc,et al.  Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein Accumulation and Propagation , 2020, The Journal of Neuroscience.

[4]  Eugene M Cilento,et al.  Immunoregulation of microglial polarization: an unrecognized physiological function of α-synuclein , 2020, Journal of neuroinflammation.

[5]  O. Chiba-Falek,et al.  The mechanistic role of alpha-synuclein in the nucleus: impaired nuclear function caused by familial Parkinson's disease SNCA mutations. , 2020, Human molecular genetics.

[6]  E. Manolakos,et al.  Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption , 2020, Nature Communications.

[7]  Yuan Luo,et al.  Interaction between ICAM1 in endothelial cells and LFA1 in T cells during the pathogenesis of experimental Parkinson's disease , 2020, Experimental and therapeutic medicine.

[8]  E. Bézard,et al.  Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. , 2020, Brain : a journal of neurology.

[9]  Q. Dong,et al.  Microglial exosomes facilitate α-synuclein transmission in Parkinson's disease. , 2020, Brain : a journal of neurology.

[10]  R. Faull,et al.  α-synuclein inclusions are abundant in non-neuronal cells in the anterior olfactory nucleus of the Parkinson’s disease olfactory bulb , 2020, Scientific Reports.

[11]  S. Mallal,et al.  α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease , 2020, Nature Communications.

[12]  F. Ginhoux,et al.  Early Fate Defines Microglia and Non-parenchymal Brain Macrophage Development , 2020, Cell.

[13]  R. Daneman,et al.  The blood–brain barrier in health and disease: Important unanswered questions , 2020, The Journal of experimental medicine.

[14]  L. Bubacco,et al.  Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson’s Disease , 2020, Frontiers in Aging Neuroscience.

[15]  Xiaomin Wang,et al.  Disease Progression-Dependent Expression of CD200R1 and CX3CR1 in Mouse Models of Parkinson’s Disease , 2020, Aging and disease.

[16]  Harald Sontheimer Parkinson Disease , 2020, Diseases of the Nervous System.

[17]  C. Dobson,et al.  The N-terminal Acetylation of α-Synuclein Changes the Affinity for Lipid Membranes but not the Structural Properties of the Bound State , 2020, Scientific Reports.

[18]  A. Planas,et al.  Defining molecular identity and fates of CNS-border associated macrophages after ischemic stroke in rodents and humans , 2020, Neurobiology of Disease.

[19]  Bin Zhang,et al.  Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration , 2019, Nature Communications.

[20]  T. Mizuno,et al.  Vessel-Associated Immune Cells in Cerebrovascular Diseases: From Perivascular Macrophages to Vessel-Associated Microglia , 2019, Front. Neurosci..

[21]  Y. Tachibana,et al.  Dual microglia effects on blood brain barrier permeability induced by systemic inflammation , 2019, Nature Communications.

[22]  Xiongwei Zhu,et al.  CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson’s disease , 2019, Journal of Neuroinflammation.

[23]  Mou-wang Zhou,et al.  Lentivirus-mediated downregulation of α-synuclein reduces neuroinflammation and promotes functional recovery in rats with spinal cord injury , 2019, Journal of Neuroinflammation.

[24]  Gaia Faustini,et al.  Alpha-Synuclein Preserves Mitochondrial Fusion and Function in Neuronal Cells , 2019, Oxidative medicine and cellular longevity.

[25]  Tuo Yang,et al.  Brain perivascular macrophages: Recent advances and implications in health and diseases , 2019, CNS neuroscience & therapeutics.

[26]  R. Maitta,et al.  Alpha synuclein in hematopoiesis and immunity , 2019, Heliyon.

[27]  M. Schwaninger,et al.  The impact of endothelial cell death in the brain and its role after stroke: A systematic review , 2019, Cell stress.

[28]  Michael M. Wang,et al.  Endothelial Targets in Stroke: Translating Animal Models to Human. , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[29]  P. Alam,et al.  α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities , 2019, Journal of neurochemistry.

[30]  T. Weissman,et al.  Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders , 2019, Scientific Reports.

[31]  S. Dohgu,et al.  Monomeric α-synuclein induces blood-brain barrier dysfunction through activated brain pericytes releasing inflammatory mediators in vitro. , 2019, Microvascular research.

[32]  Y. Saeys,et al.  A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment , 2019, Nature Neuroscience.

[33]  Xiaonan Xu,et al.  Alpha-synuclein alterations in red blood cells of peripheral blood after acute ischemic stroke. , 2019, International journal of clinical and experimental pathology.

[34]  M. Katoh,et al.  CD157 and CD200 at the crossroads of endothelial remodeling and immune regulation. , 2019, Stem cell investigation.

[35]  Yanjiang Wang,et al.  Plasma α‐synuclein levels are increased in patients with obstructive sleep apnea syndrome , 2019, Annals of clinical and translational neurology.

[36]  Ming Lu,et al.  Blocking meningeal lymphatic drainage aggravates Parkinson’s disease-like pathology in mice overexpressing mutated α-synuclein , 2019, Translational Neurodegeneration.

[37]  Paramita Chakrabarty,et al.  α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease , 2019, Acta Neuropathologica.

[38]  Tuan Leng Tay,et al.  Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation , 2019, Science.

[39]  F. N. Emamzadeh,et al.  Cell Responses to Extracellular α-Synuclein , 2019, Molecules.

[40]  M. Spillantini,et al.  Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology , 2019, International journal of molecular sciences.

[41]  Mary S. Lopez,et al.  The microRNA miR-7a-5p ameliorates ischemic brain damage by repressing α-synuclein , 2018, Science Signaling.

[42]  M. Neunlist,et al.  Enteric alpha-synuclein expression is increased in Crohn’s disease , 2018, Acta Neuropathologica.

[43]  P. Spano,et al.  Synapsin III is a key component of α‐synuclein fibrils in Lewy bodies of PD brains , 2018, Brain pathology.

[44]  Cemil Kerimoglu,et al.  Alpha-synuclein deregulates the expression of COL4A2 and impairs ER-Golgi function , 2018, Neurobiology of Disease.

[45]  C. Marshall,et al.  Deep cervical lymph node ligation aggravates AD‐like pathology of APP/PS1 mice , 2018, Brain pathology.

[46]  S. Kügler,et al.  Nuclear localization and phosphorylation modulate pathological effects of alpha‐synuclein , 2018, Human molecular genetics.

[47]  C. Lewis,et al.  Perivascular macrophages in health and disease , 2018, Nature Reviews Immunology.

[48]  Á. Chamorro,et al.  CNS-border associated macrophages respond to acute ischemic stroke attracting granulocytes and promoting vascular leakage , 2018, Acta Neuropathologica Communications.

[49]  M. Romero-Ramos,et al.  Microglia Response During Parkinson’s Disease: Alpha-Synuclein Intervention , 2018, Front. Cell. Neurosci..

[50]  C. Murray,et al.  On the road to universal health care in Indonesia, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet.

[51]  Scott T. Acton,et al.  Functional aspects of meningeal lymphatics in aging and Alzheimer’s disease , 2018, Nature.

[52]  N. Mohandas Function and dysfunction. , 2018, Blood.

[53]  E. Janda,et al.  Microglial Phagocytosis and Its Regulation: A Therapeutic Target in Parkinson’s Disease? , 2018, Front. Mol. Neurosci..

[54]  B. Becher,et al.  High‐Dimensional Single‐Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease , 2018, Immunity.

[55]  K. Plate,et al.  Functional morphology of the blood-brain barrier in health and disease , 2018, Acta Neuropathologica.

[56]  Joseph R. Madsen,et al.  VEGF Signaling in Neurological Disorders , 2018, International journal of molecular sciences.

[57]  R. Thorne,et al.  Molecular characterization of perivascular drainage pathways in the murine brain , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[58]  Jie Yin,et al.  The Role of Microglia and Macrophages in CNS Homeostasis, Autoimmunity, and Cancer , 2017, Journal of immunology research.

[59]  P. Spano,et al.  Mitochondria and α-Synuclein: Friends or Foes in the Pathogenesis of Parkinson’s Disease? , 2017, Genes.

[60]  Shao Li,et al.  Integrin CD11b mediates α-synuclein-induced activation of NADPH oxidase through a Rho-dependent pathway , 2017, Redox biology.

[61]  M. Goedert,et al.  Neurodegeneration and the ordered assembly of α-synuclein , 2017, Cell and Tissue Research.

[62]  Eyal Oren,et al.  Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, The Lancet. Neurology.

[63]  N. Sharma,et al.  Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson’s disease model , 2017, Inflammopharmacology.

[64]  P. Spano,et al.  The End Is the Beginning: Parkinson’s Disease in the Light of Brain Imaging , 2017, Front. Aging Neurosci..

[65]  Wei He,et al.  Mitophagy in Parkinson’s Disease: Pathogenic and Therapeutic Implications , 2017, Front. Neurol..

[66]  M. Dragunow,et al.  Endothelial Degeneration of Parkinson's Disease is Related to Alpha-Synuclein Aggregation , 2017 .

[67]  W. Banks,et al.  Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson’s disease? , 2017, Acta Neuropathologica Communications.

[68]  T. Falzone,et al.  Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein? , 2017, Disease Models & Mechanisms.

[69]  K. Prasad Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson's Disease. , 2017, Current aging science.

[70]  C. Zurzolo,et al.  α-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading , 2017, Acta Neuropathologica.

[71]  M. Gessler,et al.  Gene expression profiles of brain endothelial cells during embryonic development at bulk and single-cell levels , 2017, Science Signaling.

[72]  J. Kordower,et al.  Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins , 2017, Acta Neuropathologica.

[73]  M. Goedert,et al.  The Synucleinopathies: Twenty Years On , 2017, Journal of Parkinson's disease.

[74]  R. Faull,et al.  α-synuclein transfer through tunneling nanotubes occurs in SH-SY5Y cells and primary brain pericytes from Parkinson’s disease patients , 2017, Scientific Reports.

[75]  Ole Isacson,et al.  The Threshold Theory for Parkinson's Disease , 2017, Trends in Neurosciences.

[76]  P. Spano,et al.  The Contribution of α-Synuclein Spreading to Parkinson's Disease Synaptopathy , 2017, Neural plasticity.

[77]  R. Barker,et al.  α-Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function , 2016, Experimental Neurology.

[78]  T. Outeiro,et al.  Structure, function and toxicity of alpha‐synuclein: the Bermuda triangle in synucleinopathies , 2016, Journal of neurochemistry.

[79]  T. Heurtaux,et al.  Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant , 2016, PloS one.

[80]  Sean Regan,et al.  Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease , 2016, Neurobiology of Disease.

[81]  L. Rénia,et al.  Tissue-Resident CD169(+) Macrophages Form a Crucial Front Line against Plasmodium Infection. , 2016, Cell reports.

[82]  Mieke Dewerchin,et al.  Vascular endothelial growth factor: a neurovascular target in neurological diseases , 2016, Nature Reviews Neurology.

[83]  R. Dempsey,et al.  Poststroke Induction of α-Synuclein Mediates Ischemic Brain Damage , 2016, The Journal of Neuroscience.

[84]  B. Zlokovic,et al.  Pericytes of the neurovascular unit: key functions and signaling pathways , 2016, Nature Neuroscience.

[85]  L. Luo,et al.  Macrophages Mediate the Repair of Brain Vascular Rupture through Direct Physical Adhesion and Mechanical Traction. , 2016, Immunity.

[86]  D. Standaert,et al.  Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration , 2016, The Journal of Neuroscience.

[87]  S. Linnarsson,et al.  Origin, fate and dynamics of macrophages at central nervous system interfaces , 2016, Nature Immunology.

[88]  V. Baekelandt,et al.  ɑ‐Synuclein strains and the variable pathologies of synucleinopathies , 2016, Journal of neurochemistry.

[89]  B. Engelhardt,et al.  Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke. , 2016, Biochimica et biophysica acta.

[90]  F. Wendler,et al.  Extracellular vesicles round off communication in the nervous system , 2016, Nature Reviews Neuroscience.

[91]  Annalena Venneri,et al.  Review: Parkinson's disease: from synaptic loss to connectome dysfunction , 2016, Neuropathology and applied neurobiology.

[92]  Fang-fei Li,et al.  A comparative study of the amount of α-synuclein in ischemic stroke and Parkinson’s disease , 2016, Neurological Sciences.

[93]  M. Wegrzynowicz,et al.  Synaptic failure and α‐synuclein , 2016, Movement disorders : official journal of the Movement Disorder Society.

[94]  Takahiro Takano,et al.  Purinergic receptor P2RY12-dependent microglial closure of the injured blood–brain barrier , 2016, Proceedings of the National Academy of Sciences.

[95]  Paul J. Barrett,et al.  Post-translational modification of α-synuclein in Parkinson׳s disease , 2015, Brain Research.

[96]  M. Spillantini,et al.  Parkinson's disease as a member of Prion-like disorders. , 2015, Virus research.

[97]  M. Giugliano,et al.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration , 2015, Nature.

[98]  H. Lashuel,et al.  Elucidating the Role of Site-Specific Nitration of α-Synuclein in the Pathogenesis of Parkinson's Disease via Protein Semisynthesis and Mutagenesis. , 2015, Journal of the American Chemical Society.

[99]  P. Spano,et al.  Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? , 2015, Parkinson's disease.

[100]  Tessandra H Stewart,et al.  α-Synuclein, a chemoattractant, directs microglial migration via H2O2-dependent Lyn phosphorylation , 2015, Proceedings of the National Academy of Sciences.

[101]  J. Woulfe,et al.  Striatal Blood–Brain Barrier Permeability in Parkinson'S Disease , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[102]  E. Schon,et al.  Novel subcellular localization for α-synuclein: possible functional consequences , 2015, Front. Neuroanat..

[103]  W. Banks,et al.  Alpha synuclein is transported into and out of the brain by the blood–brain barrier , 2014, Peptides.

[104]  Wei Zheng,et al.  Brain disposition of α-Synuclein: roles of brain barrier systems and implications for Parkinson’s disease , 2014, Fluids and Barriers of the CNS.

[105]  K. Blennow,et al.  Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[106]  Nan Li,et al.  Exosomes of BV-2 cells induced by alpha-synuclein: Important mediator of neurodegeneration in PD , 2013, Neuroscience Letters.

[107]  M. Prinz,et al.  Factors regulating microglia activation , 2013, Front. Cell. Neurosci..

[108]  C. Green,et al.  Vascular Degeneration in Parkinson's Disease , 2013, Brain pathology.

[109]  Collin M. Stultz,et al.  The dynamic structure of α-synuclein multimers. , 2013, Journal of the American Chemical Society.

[110]  Nam Ki Lee,et al.  Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking , 2013, Proceedings of the National Academy of Sciences.

[111]  DelindaA . Johnson,et al.  Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-Synuclein , 2012, Journal of Neuroimmune Pharmacology.

[112]  P. Spano,et al.  From α-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease , 2012, Brain Research.

[113]  G. Vivacqua,et al.  The role of alpha-synuclein in neurotransmission and synaptic plasticity , 2011, Journal of Chemical Neuroanatomy.

[114]  Jianqing Ding,et al.  CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease , 2011, Journal of Neuroinflammation.

[115]  Yuzhang Wu,et al.  Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains , 2011, Journal of Neuroimmunology.

[116]  J. Clarke,et al.  What is a systematic review? , 2011, Evidence Based Nursing.

[117]  H. Tanila,et al.  Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein , 2011, Brain Research.

[118]  S. Lule,et al.  Alpha-Synuclein Aggregation Induced by Brief Ischemia Negatively Impacts Neuronal Survival in vivo: A Study in [A30P]alpha-Synuclein Transgenic Mouse , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[119]  B. Ghetti,et al.  Presence of Reactive Microglia and Neuroinflammatory Mediators in a Case of Frontotemporal Dementia with P301S Mutation , 2011, Neurodegenerative Diseases.

[120]  Longxuan Li,et al.  Microglial activation state exerts a biphasic influence on brain endothelial cell proliferation by regulating the balance of TNF and TGF-β1 , 2010, Journal of Neuroinflammation.

[121]  Logan S. Ahlstrom,et al.  The N-terminus of the intrinsically disordered protein α-synuclein triggers membrane binding and helix folding. , 2010, Biophysical journal.

[122]  J. Waschke,et al.  Role of GTPases in control of microvascular permeability. , 2010, Cardiovascular research.

[123]  J. Hay,et al.  α-Synuclein Delays Endoplasmic Reticulum (ER)-to-Golgi Transport in Mammalian Cells by Antagonizing ER/Golgi SNAREs , 2010, Molecular biology of the cell.

[124]  Ji-Young Park,et al.  Regulation of Weibel-Palade Body Exocytosis by α-Synuclein in Endothelial Cells* , 2010, The Journal of Biological Chemistry.

[125]  Jianqing Ding,et al.  Altered Regulation of CD200 Receptor in Monocyte-Derived Macrophages from Individuals with Parkinson’s Disease , 2010, Neurochemical Research.

[126]  Longxuan Li,et al.  Absence of the αvβ3 Integrin Dictates the Time-Course of Angiogenesis in the Hypoxic Central Nervous System: Accelerated Endothelial Proliferation Correlates with Compensatory Increases in α5β1 Integrin Expression , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[127]  V. V. van Hinsbergh,et al.  Driving Rho GTPase activity in endothelial cells regulates barrier integrity , 2009, Thrombosis and Haemostasis.

[128]  B. Engelhardt,et al.  The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction , 2009, Seminars in Immunopathology.

[129]  P. Lansbury,et al.  The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. , 2009, Journal of molecular biology.

[130]  K. Chung,et al.  Identification of the amino acid sequence motif of alpha-synuclein responsible for macrophage activation. , 2009, Biochemical and biophysical research communications.

[131]  D. Selkoe,et al.  Evidence that alpha-synuclein does not inhibit phospholipase D. , 2009, Biochemistry.

[132]  D. Swaab,et al.  Distribution of the Immune Inhibitory Molecules CD200 and CD200R in the Normal Central Nervous System and Multiple Sclerosis Lesions Suggests Neuron-Glia and Glia-Glia Interactions , 2009, Journal of neuropathology and experimental neurology.

[133]  Xiaomin Su,et al.  Synuclein activates microglia in a model of Parkinson's disease , 2008, Neurobiology of Aging.

[134]  R. Barbour,et al.  Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood , 2008, Neurodegenerative Diseases.

[135]  F. Gillardon,et al.  Functional protein kinase arrays reveal inhibition of p‐21‐activated kinase 4 by α‐synuclein oligomers , 2007, Journal of neurochemistry.

[136]  Jordan S. Pober,et al.  Evolving functions of endothelial cells in inflammation , 2007, Nature Reviews Immunology.

[137]  Shuzhen Guo,et al.  Cell–cell Signaling in the Neurovascular Unit , 2007, Neurochemical Research.

[138]  William C. Aird,et al.  Phenotypic Heterogeneity of the Endothelium: I. Structure, Function, and Mechanisms , 2007, Circulation research.

[139]  Seung-Jae Lee,et al.  Impairment of microtubule‐dependent trafficking by overexpression of α‐synuclein , 2006 .

[140]  J. Parvin,et al.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. , 2006, Human molecular genetics.

[141]  M. Rondaij,et al.  Dynamics and Plasticity of Weibel-Palade Bodies in Endothelial Cells , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[142]  S. Westmoreland,et al.  CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. , 2006, The American journal of pathology.

[143]  Alexander Hammers,et al.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.

[144]  M. Yamakuchi,et al.  Regulation of Weibel-Palade body exocytosis. , 2005, Trends in cardiovascular medicine.

[145]  T. K. van den Berg,et al.  CD163‐positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation , 2005, Glia.

[146]  P. Carvey,et al.  6‐Hydroxydopamine‐induced alterations in blood–brain barrier permeability , 2005, The European journal of neuroscience.

[147]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[148]  Ad Bax,et al.  Structure and Dynamics of Micelle-bound Human α-Synuclein* , 2005, Journal of Biological Chemistry.

[149]  V. Perry,et al.  Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain , 2005, Glia.

[150]  C. Dobson,et al.  Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. , 2005, Journal of the American Chemical Society.

[151]  H. Tanila,et al.  Role of α-Synuclein in Presynaptic Dopamine Recruitment , 2004, The Journal of Neuroscience.

[152]  T. Yasuhara,et al.  Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease , 2004, The European journal of neuroscience.

[153]  M. White,et al.  Ral GTPases Regulate Exocyst Assembly through Dual Subunit Interactions* , 2003, Journal of Biological Chemistry.

[154]  Andre Parent,et al.  Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration , 2003, Annals of neurology.

[155]  K. Wakabayashi,et al.  Expression of α-synuclein in vascular endothelial and smooth muscle cells , 2003 .

[156]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[157]  G. Halliday,et al.  An inflammatory review of Parkinson’s disease , 2002, Progress in Neurobiology.

[158]  Hitoshi Takahashi,et al.  Upregulation of α‐synuclein by lipopolysaccharide and interleukin‐1 in human macrophages , 2002 .

[159]  Hitoshi Takahashi,et al.  Expression of α-synuclein, the precursor of non-amyloid β component of Alzheimer's disease amyloid, in human cerebral blood vessels , 2002, Neuroscience Letters.

[160]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[161]  U. Dirnagl,et al.  Immune surveillance of mouse brain perivascular spaces by blood‐borne macrophages , 2001, The European journal of neuroscience.

[162]  板部 洋之 VCAM-1(Vascular cell adhesion molecule-1( 生活習慣病) , 2001 .

[163]  J Q Trojanowski,et al.  A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.

[164]  M. Goedert,et al.  The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy , 2000 .

[165]  R. Vos,et al.  Pathological features of cerebral cortical capillaries are doubled in Alzheimer’s disease and Parkinson’s disease , 2000, Acta Neuropathologica.

[166]  M. Tabaton,et al.  Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects , 2000, Neuroscience Letters.

[167]  B. Giasson,et al.  Chaperone‐like activity of synucleins , 2000, FEBS letters.

[168]  M. Hur,et al.  Expression Patterns of α-Synuclein in Human Hematopoietic Cells and in Drosophila at Different Developmental Stages , 2000 .

[169]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[170]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[171]  E. Masliah,et al.  NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. , 1997, Biochemical and biophysical research communications.

[172]  P. Lansbury,et al.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.

[173]  R. Burke,et al.  Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[174]  P. Riederer,et al.  Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.

[175]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[176]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[177]  B. Mcguinness,et al.  Twenty years on. , 1976, British medical journal.

[178]  Florey,et al.  The endothelial cell. , 1966, British medical journal.

[179]  M. Ho Microglia in Parkinson's Disease. , 2019, Advances in experimental medicine and biology.

[180]  D. Thao,et al.  Parkinson's Disease Model. , 2018, Advances in experimental medicine and biology.

[181]  Mike Dragunow,et al.  String Vessel Formation is Increased in the Brain of Parkinson Disease. , 2015, Journal of Parkinson's disease.

[182]  R. Daneman,et al.  The blood-brain barrier. , 2015, Cold Spring Harbor perspectives in biology.

[183]  W. Aird,et al.  Endothelial cell heterogeneity. , 2012, Cold Spring Harbor perspectives in medicine.

[184]  Julie A. Schneider,et al.  Evidence for angiogenesis in Parkinson’s disease, incidental Lewy body disease, and progressive supranuclear palsy , 2011, Journal of Neural Transmission.

[185]  K. Leenders,et al.  [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? , 2010, Parkinsonism & related disorders.

[186]  D. Selkoe,et al.  Evidence that α -Synuclein Does Not Inhibit Phospholipase D † , 2009 .

[187]  Taro Saito,et al.  Demonstration of a role for α-synuclein as a functional microtubule-associated protein , 2004 .

[188]  C. Culmsee,et al.  Neuronal apoptosis in Alzheimer ’ s disease , 2001 .

[189]  H. Ichinose,et al.  Cytokines in Parkinson’s Disease , 2000 .